The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR oldest and largest oldest and largest professional organization dedicated to advancing cancer research generic sildenafil citrate . Membership includes more than 24,000 basic, translational and clinical researchers, health professionals and cancer survivors and advocates in the United States and more than 70 other countries. AACR marshals the full spectrum of expertise from the cancer community progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants to the latest discoveries and developments in the area equities. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. AACR publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer Research, Molecular Cancer Therapeutics, Molecular Cancer Research and Cancer Epidemiology, Biomarkers & Prevention. His most recent publication is a magazine for cancer survivors, patient advocates, their families, physicians and scientists. It provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
In the February 1 issue of Clinical Cancer Research , the researchers found that only nine of the 70 Phase II studies they examined clearly defined measures were judged by an experimental drug may offer benefits for patients. We are facing a new and growing problem in clinical trial testing, and that is, while the changed changed, researchers assessed still using the same old methods, how effective they are, said the study’s lead author, Andrew Vickers, a research methodologist. The problem, Vickers said that for so long, therapies by seeing if tumors would shrink in patients with cancer in advanced stage were tested. Measurement These studies, whichwas an accepted method to estimate benefits, he said. But today’s new treatments, targeted treatments that slow tumor progression, are often may include testing in less advanced cancer and in combinations , and it can be difficult, whether it to respond to respond better than expected, said it. [Read the rest of this entry...]